BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 20875382)

  • 1. High dose urokinase for restoration of patency of occluded permanent central venous catheters in hemodialysis patients.
    Shavit L; Lifschitz M; Plaksin J; Grenader T; Slotki I
    Clin Nephrol; 2010 Oct; 74(4):297-302. PubMed ID: 20875382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose intradialytic urokinase to restore the patency of permanent central vein hemodialysis catheters.
    Twardowski ZJ
    Am J Kidney Dis; 1998 May; 31(5):841-7. PubMed ID: 9590195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant urokinase for restoration of patency in occluded central venous access devices. A double-blind, placebo-controlled trial.
    Haire WD; Deitcher SR; Mullane KM; Jaff MR; Firszt CM; Schulz GA; Schuerr DM; Schwartz LB; Mouginis TL; Barton RP
    Thromb Haemost; 2004 Sep; 92(3):575-82. PubMed ID: 15351854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of urokinase lock to treat thrombotic dysfunction of tunneled hemodialysis catheters: A retrospective cohort study.
    Van Hulle F; Bonkain F; De Clerck D; Aerden D; Vanwijn I; Tielemans C; Wissing KM
    J Vasc Access; 2019 Jan; 20(1):60-69. PubMed ID: 29893163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alteplase versus urokinase for occluded hemodialysis catheters.
    Zacharias JM; Weatherston CP; Spewak CR; Vercaigne LM
    Ann Pharmacother; 2003 Jan; 37(1):27-33. PubMed ID: 12503929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant urokinase is safe and effective in restoring patency to occluded central venous access devices: a multiple-center, international trial.
    Svoboda P; Barton RP; Barbarash OL; Butylin AA; Jacobs BR; Lata J; Haire WD; Jaff MR; Firszt CM; Mouginis TL; Schuerr DM; Schulz GA; Schwartz LB; El-Shahawy MA
    Crit Care Med; 2004 Oct; 32(10):1990-6. PubMed ID: 15483405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urokinase efficacy in the restoration of hemodialysis catheter function.
    Meers C; Toffelmire EB
    J CANNT; 1998; 8(2):17-9. PubMed ID: 9807329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective Audit to Study urokinaSe use to restore Patency in Occluded centRal venous caTheters (PASSPORT 1).
    Kumwenda MJ; Mitra S; Khawaja A; Inston N; Nightingale P
    J Vasc Access; 2019 Nov; 20(6):752-759. PubMed ID: 31466489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alteplase vs. urokinase for occluded hemodialysis catheter: A randomized trial.
    Pollo V; Dionízio D; Bucuvic EM; Castro JH; Ponce D
    Hemodial Int; 2016 Jul; 20(3):378-84. PubMed ID: 26851872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetes decreases patency of tunneled catheters in hemodialysis patients after first effective thrombolysis with urokinase.
    Wójtowicz D; Cholewa D; Faba AM; Domańska B; Kokoszka J; Kopacz K; Ficek R; Irzyniec T; Rotkegel SE; Chudek J
    Ren Fail; 2018 Nov; 40(1):384-389. PubMed ID: 30010473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term continuous infusion thrombolytic therapy for occluded central nervous venous dialysis catheters.
    Peska DN; DeLange B; Gratch JO; Bleicher JN; Pertusi RM; Mueller D
    Am J Manag Care; 1997 Feb; 3(2):261-4. PubMed ID: 10169260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombosis of tunneled-cuffed hemodialysis catheters: treatment with high-dose urokinase lock therapy.
    Donati G; Colì L; Cianciolo G; La Manna G; Cuna V; Montanari M; Gozzetti F; Stefoni S
    Artif Organs; 2012 Jan; 36(1):21-8. PubMed ID: 21848863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective Audit to Study urokinaSe use to restore Patency in Occluded centRal venous caTheters in haematology and oncology patients (PASSPORT 2).
    Kumwenda MJ; Dougherty L; Jackson A; Hill S
    J Vasc Access; 2021 Jul; 22(4):568-574. PubMed ID: 32867568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of tunneled cuffed catheter dysfunction with prophylactic use of a taurolidine urokinase lock: A randomized double-blind trial.
    Bonkain F; Stolear JC; Catalano C; Vandervelde D; Treille S; Couttenye MM; Dhondt A; Libertalis M; Allamani M; Madhoun P; Van Craenenbroeck AH; Vanommeslaeghe F; Van Hulle F; Durieux P; Van Limberghen I; Tielemans C; Wissing KM
    PLoS One; 2021; 16(5):e0251793. PubMed ID: 34015014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using urokinase to restore patency in double lumen catheters.
    Northsea C
    ANNA J; 1994 Aug; 21(5):261-4, 273. PubMed ID: 8080337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alteplase versus urokinase in restoring blood flow in hemodialysis-catheter thrombosis.
    Eyrich H; Walton T; Macon EJ; Howe A
    Am J Health Syst Pharm; 2002 Aug; 59(15):1437-40. PubMed ID: 12166043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombolysis for restoration of patency to haemodialysis central venous catheters: a systematic review.
    Clase CM; Crowther MA; Ingram AJ; Cinà CS
    J Thromb Thrombolysis; 2001 Apr; 11(2):127-36. PubMed ID: 11406727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Complications related to permanent deep venous catheterization using dual lumen hemodialysis catheter].
    Zhang P; Yuan J; Chen JH; Wu JY; Zhang XH; Jiang H
    Zhonghua Nei Ke Za Zhi; 2004 Mar; 43(3):198-200. PubMed ID: 15059375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interventions for restoring patency of occluded central venous catheter lumens.
    van Miert C; Hill R; Jones L
    Cochrane Database Syst Rev; 2012 Apr; 2012(4):CD007119. PubMed ID: 22513946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemodialysis catheter design and catheter performance: a randomized controlled trial.
    Van Der Meersch H; De Bacquer D; Vandecasteele SJ; Van den Bergh B; Vermeiren P; De Letter J; De Vriese AS
    Am J Kidney Dis; 2014 Dec; 64(6):902-8. PubMed ID: 24713222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.